Incyte stock heads into the open after a 2.5% gain
Published on 09/18/2026 at 03:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte stock closed at USD 124.75 on Nasdaq on September 16, 2026, rising 2.47% from the prior close according to data on the company’s quote page at Yahoo Finance. The latest close left the shares near the upper end of their 52-week corridor between USD 81.09 and USD 132.60, illustrating that Incyte is trading closer to its recent highs than its lows.
September 16, 2026 in numbers
Incyte Corp. (ISIN US45337C1027) recorded its most recent completed session on Nasdaq on September 16, 2026, when it closed at USD 124.75, up 3.01 dollars or 2.47% on the day per Nasdaq data reflected on Yahoo Finance. The 52-week range of USD 81.09 to USD 132.60 places the latest close roughly 54% above the 52-week low and about 6% below the 52-week high, underscoring that the stock is trading near the upper band of its one-year span, as highlighted in a market wrap on Incyte’s recent performance by Ad-hoc-news. In the same wrap, the outlet noted that Incyte’s year-to-date gain of 26.3% at that close outpaced many broader healthcare names, which adds context to the stock’s elevated positioning within its recent trading band.
The broader Nasdaq Composite delivered a firm session around the same time, advancing about 1.76% to close at 26,434.77 as reported in a technology-led market summary by Scanx.trade. Measured against that move, Incyte’s roughly 2.47% rise slightly exceeded the Nasdaq’s gain, indicating that the stock participated in the broader rebound while adding an incremental performance premium over its reference index in that completed session.
Today’s context for Incyte stock
Company-specific filings show that on September 15, 2026, an Incyte insider executed a pre-arranged sale of 23,218 shares at prices near USD 120.50 per share, according to an insider trading disclosure summarized by StockTitan. While this transaction preceded the latest close, it remains part of the recent news flow investors may weigh when assessing governance and insider activity around the stock. In parallel, valuation commentary pointing to a fair value moderately above the latest close has framed Incyte as trading at only a small discount to some analyst estimates, as noted in a healthcare sector analysis on the company by Yahoo Finance. These elements of the recent narrative, combined with a supportive technology and growth backdrop on the Nasdaq, set the scene for Incyte stock as it heads into today’s US session without a specific, dated corporate event dominating the near-term calendar.
